Donald Bushnell
Don has over 20 years’ experience in global clinical and health outcomes research, specializing in instrument development and validation. He has recently supported scientific work on symptom measures of depression (Symptoms of Major Depressive Disorder Scale, SMDDS) and non-small cell lung cancer (Non-Small Cell Lung Cancer-Symptoms Assessment Questionnaire, NSCLC-SAQ); both having been qualified by the FDA’s Center for Drug Evaluation and Research. He has been on the development team and provided psychometric validation for well-known measures such as the Psoriasis Symptom Inventory (PSI), Incontinence-specific Quality of Life (I-QOL), the World Health Organization Quality of Life (WHOQOL), the Parkinson’s Disease Questionnaire (PDQ), the Irritable Bowel Syndrome Quality of Life (IBS-QOL), the Obesity and Weight Loss QOL Measure (OWLQOL) and Migraine Treatment Satisfaction measure (MTS). Don has designed and supported the data management and analysis for a variety of large international studies including the Longitudinal Investigation of Depression Outcomes (LIDO). He has also conducted extensive research in the area of electronic data capture (EDC) and equivalence on numerous different platforms.
Don received his Masters of Arts degree from the University of Washington (UW). He served as the data manager and analyst for the CDC-funded Northwest Prevention Effectiveness Center at the UW from 1986 until 1995 before becoming the director of data management and analysis at HRA, Inc.
Don has authored and co-authored numerous quality of life publications and has both supported and presented a wide range of research findings. He is a member of the International Society for Quality of Life Research, the International Society for Pharmacoeconomic Outcomes Research as well as a peer reviewer for the journals Quality of Life Research, Journal of Clinical Epidemiology, and PharmacoEconomics.